Prenetics Global (PRE) Projected to Post Earnings on Wednesday

Prenetics Global (NASDAQ:PRE) is anticipated to issue its Q4 2025 results before the market opens on Wednesday, February 18th. Analysts expect the company to announce earnings of ($0.49) per share and revenue of $36.15 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, February 18, 2026 at 10:00 AM ET.

Prenetics Global Stock Up 4.8%

Shares of PRE stock opened at $21.97 on Tuesday. Prenetics Global has a 12-month low of $3.09 and a 12-month high of $22.86. The firm has a fifty day moving average of $17.41 and a 200-day moving average of $13.74. The firm has a market capitalization of $369.76 million, a price-to-earnings ratio of -10.82 and a beta of 0.35.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on PRE shares. Roth Mkm initiated coverage on Prenetics Global in a research report on Wednesday, February 11th. They set a “buy” rating and a $36.00 price target on the stock. Cantor Fitzgerald upped their price target on shares of Prenetics Global from $26.00 to $32.00 and gave the company an “overweight” rating in a report on Wednesday, October 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prenetics Global in a research report on Thursday, January 22nd. Finally, Wall Street Zen cut Prenetics Global from a “buy” rating to a “hold” rating in a report on Monday. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Prenetics Global presently has an average rating of “Hold” and an average price target of $34.00.

Institutional Trading of Prenetics Global

Institutional investors and hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. bought a new position in Prenetics Global in the third quarter valued at approximately $65,000. UBS Group AG grew its stake in shares of Prenetics Global by 581.9% in the third quarter. UBS Group AG now owns 46,561 shares of the company’s stock valued at $619,000 after buying an additional 39,733 shares in the last quarter. Goldman Sachs Group Inc. bought a new position in shares of Prenetics Global in the fourth quarter valued at $665,000. Jane Street Group LLC acquired a new position in Prenetics Global during the fourth quarter worth $1,302,000. Finally, Wells Fargo & Company MN bought a new stake in Prenetics Global during the fourth quarter worth $47,000. Institutional investors own 25.01% of the company’s stock.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.